Purple Biotech Ltd. – NASDAQ:PPBT
Purple Biotech Ltd. stock price today
Purple Biotech Ltd. stock price monthly change
Purple Biotech Ltd. stock price quarterly change
Purple Biotech Ltd. stock price yearly change
Purple Biotech Ltd. key metrics
Market Cap | 8.26M |
Enterprise value | 20.05M |
P/E | -1.54 |
EV/Sales | N/A |
EV/EBITDA | -1.04 |
Price/Sales | N/A |
Price/Book | 0.73 |
PEG ratio | 0.10 |
EPS | -0.83 |
Revenue | N/A |
EBITDA | -20.58M |
Income | -18.76M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePurple Biotech Ltd. stock price history
Purple Biotech Ltd. stock forecast
Purple Biotech Ltd. financial statements
| Jun 2023 | 0 | -5.13M | |
|---|---|---|---|
| Sep 2023 | 0 | -5.03M | |
| Dec 2023 | 0 | -4.82M | |
| Mar 2024 | 0 | -3.76M |
| 2025 | 0 | -17M | |
|---|---|---|---|
| 2026 | 7.7M | -10.58M | -137.48% |
| 2027 | 36.4M | -6.15M | -16.91% |
| 2028 | 60.6M | -3.93M | -6.5% |
Analysts Price target
Financials & Ratios estimates
| 2023-02-08 | -0.3 | -0.3 |
|---|---|---|
| 2023-05-16 | -0.36 | -0.25 |
| Jun 2023 | 47999000 | 5.25M | 10.95% |
|---|---|---|---|
| Sep 2023 | 45272000 | 6.55M | 14.47% |
| Dec 2023 | 44302000 | 10.00M | 22.58% |
| Mar 2024 | 39863000 | 8.77M | 22.01% |
| Jun 2023 | -5.22M | 198K | 367K |
|---|---|---|---|
| Sep 2023 | -3.65M | 1.00M | 572K |
| Dec 2023 | -4.91M | -5.99K | 4.26M |
| Mar 2024 | -4.96M | 187K | 278.99K |
Purple Biotech Ltd. alternative data
| Aug 2023 | 20 |
|---|---|
| Sep 2023 | 20 |
| Oct 2023 | 20 |
| Nov 2023 | 20 |
| Dec 2023 | 20 |
| Jan 2024 | 20 |
| Feb 2024 | 20 |
| Mar 2024 | 20 |
| Apr 2024 | 20 |
| May 2024 | 20 |
| Jun 2024 | 20 |
| Jul 2024 | 20 |
Purple Biotech Ltd. other data
-
What's the price of Purple Biotech Ltd. stock today?
One share of Purple Biotech Ltd. stock can currently be purchased for approximately $2.31.
-
When is Purple Biotech Ltd.'s next earnings date?
Unfortunately, Purple Biotech Ltd.'s (PPBT) next earnings date is currently unknown.
-
Does Purple Biotech Ltd. pay dividends?
No, Purple Biotech Ltd. does not pay dividends.
-
How much money does Purple Biotech Ltd. make?
Purple Biotech Ltd. has a market capitalization of 8.26M. Purple Biotech Ltd. made a loss 19.88M US dollars in net income (profit) last year or -$0.25 on an earnings per share basis.
-
What is Purple Biotech Ltd.'s stock symbol?
Purple Biotech Ltd. is traded on the NASDAQ under the ticker symbol "PPBT".
-
What is Purple Biotech Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Purple Biotech Ltd.?
Shares of Purple Biotech Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Purple Biotech Ltd. have?
As Jul 2024, Purple Biotech Ltd. employs 20 workers.
-
When Purple Biotech Ltd. went public?
Purple Biotech Ltd. is publicly traded company for more then 9 years since IPO on 20 Nov 2015.
-
What is Purple Biotech Ltd.'s official website?
The official website for Purple Biotech Ltd. is purple-biotech.com.
-
How can i contact Purple Biotech Ltd.?
Purple Biotech Ltd. can be reached via phone at +972 3 933 3121.
Purple Biotech Ltd. company profile:
Purple Biotech Ltd.
purple-biotech.comNASDAQ
20
Biotechnology
Healthcare
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Rehovot, 7670104
CIK: 0001614744
ISIN: US74638P1093
CUSIP: 74638P109
